Last reviewed 2026-04-19 · How we verify

Rheumatoid Arthritis

Approved treatments

• Aurolate
• Sofenac
  Sofenac works by inhibiting the COX-2 enzyme, which reduces inflammation and pain.
• Magan
• Celebrex · Pfizer Inc. (originally Searle/Pharmacia)
  Celecoxib works by inhibiting COX-2 to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
• Sasapyrine
  Salsalate works by inhibiting the enzyme COX-1 and COX-2, which are responsible for producing prostaglandins.
• DEXIBUPROFEN
• Trilisate
  Trilisate works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.
• TENIDAP
  TENIDAP works by inhibiting the enzyme Prostaglandin G/H synthase 1, which plays a key role in the production of inflammatory mediators.
• Afloxan
  Afloxan works by inhibiting the activity of enzymes called lipoxygenases, which play a role in the production of inflammatory mediators.
• (S)-Flunoxaprofen
  Flunoxaprofen is thought to work by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
• In open-label phase: treatment with tofacitinib · Pfizer
• tumor necrosis factor inhibitors (TNFi) · Pfizer
• Nalfon · Pharmaco
• Solu-Cortef · Pfizer
• Hydroxychloroquine Sulfate · Sanofi
  Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases.
• Nanozora · Taisho Pharmaceutical Co., Ltd.
• Imuran · Legacy Pharma
• Olumiant · Eli Lilly
• Abrilada · AbbVie
  Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• Cortifoam · Pfizer
• Voltaren · Hisamitsu Pharmaceutical Co., Inc
• Sandimmune · Novartis
• Arava · Sanofi
  Arava works by inhibiting the enzyme Cytochrome P450 1A2, which is involved in the production of inflammatory chemicals in the body.
• Cortone
• Orencia · Bristol-Myers Squibb
  Abatacept inhibits T-cell activation by binding CD80/CD86, blocking CD28 costimulatory interaction.
• Mabthera · Roche
• Aureotan
• Celestone Soluspan
• Decadron · Generic (originally Merck)
• Reufenac
• Tasocitinib · Pfizer
• Humira · AbbVie
  Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.
• TNF Inhibitor · Pfizer
• Indom · University of Trieste
• Sandimmune · Novartis AG (originally Sandoz)
  Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection.
• Loxonin · Lead Chemical Co., Ltd.
• ciclosporine · Hospices Civils de Lyon
• Cimzia · UCB
  Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity.
• Remicade · Johnson & Johnson
  Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses.
• Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
• prednison · Wen Zhang
• Anakinra · Biovitrum Ab
• Azulfidine En-Tabs · Pfizer
• Remicade · Johnson & Johnson
  Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding.
• CYLTEZO · BOEHRINGER INGELHEIM
• IXIFI · PFIZER INC
• Olumiant · NHS Greater Glasgow and Clyde
• Orencia · Bristol-Myers Squibb
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Oraflex

Pipeline

• ocrelizumabu 200mg · Chugai Pharmaceutical — Phase 2

Clinical guidelines

• FDA label — 1L|2L
  Sulfasalazine is indicated for the treatment of rheumatoid arthritis.
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 1L|2L
  Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
• FDA label — 2L
  reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease in combination with methotrexate.
• FDA label — 1L|2L
  Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
• FDA label — 1L
  Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone.
• FDA label — 1L
  Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
• FDA label — 1L
  Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in adult patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate.
• FDA label — 1L
  Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
• FDA label — 2L
  XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
• FDA label — 2L
  RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
• FDA label — 2L
  RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
• FDA label — 2L
  RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker.
• FDA label — 1L
  For relief of the signs and symptoms of rheumatoid arthritis
• FDA label — any
  ORENCIA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
• FDA label — any
  Ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis.
• FDA label — any
  Ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of osteoarthritis.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Rheumatoid Arthritis patent landscape — cliff calendar, originator estates, attackable patents
• Rheumatoid Arthritis treatment landscape brief
• Rheumatoid Arthritis treatment updates RSS

Frequently asked questions about Rheumatoid Arthritis

Related

• Therapeutic area: All conditions in Immunology & Inflammation
• Treatment landscape: Rheumatoid Arthritis patent cliff · Rheumatoid Arthritis CI report
• Treatment: Aurolate
• Treatment: Sofenac
• Treatment: Magan
• Treatment: Celebrex · Pfizer Inc. (originally Searle/Pharmacia)
• Treatment: Sasapyrine
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing